Keyword Index to Assist Manufacturers in Verifying the Class of Medical Devices
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Rectal Suppository & Enema Administration to Administration Unlicensed Assistive Personnel (UAP) Module/Skill Checklist
Delegation of Medication Rectal Suppository & Enema Administration to Administration Unlicensed Assistive Personnel (UAP) Module/Skill Checklist Objective At the completion of this module, the UAP should be able to administer rectal suppository & enema medications. NOTE: 1) The RN or LPN is permitted to delegate ONLY after application of all components of the NCBON Decision Tree for Delegation to UAP and after careful consideration that delegation is appropriate: a) for this client, b) with this acuity level, c) with this individual UAP’s knowledge and experience, and d) now (or in the time period being planned). 2) Successful completion of the “Infection Control” module by the UAP should be documented prior to instruction in medication administration by this or ANY route. Procedure for: SUPPOSITORY 1. Perform skills in General Medication Administration Checklist. 2. Provide privacy. Have client void before procedure. 3. Put on clean gloves. 4. Position the client on their left (preferred) side with the top leg bent slightly. 5. Remove the foil or wrapper from the suppository, if present. 6. Apply a small amount of lubricant to the suppository and your gloved index finger on your dominant hand – the hand holding the suppository. 7. Separate the buttocks with your gloved, non dominant hand. 8. Ask the client to breathe slowly and deeply through the mouth. 9. Place tip of suppository against anus and gently insert the suppository about 4- inches along the rectal wall. Avoid putting the suppository in stool. 10. After removing your finger, squeeze buttocks together for a few minutes to help client hold in the suppository for as long as possible. -
B.J.ZH.F.Panther Medical Equipment Co., Ltd. 北京派爾特醫療科技股份
The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of B.J.ZH.F.Panther Medical Equipment Co., Ltd. 北京派爾特醫療科技股份有限公司 (the “Company”) (a joint stock company incorporated in the People’s Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Securities and Futures Commission (the “Commission”) solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its sole sponsor, advisors or members of the underwriting syndicate that: (a) this document is only for the purpose of providing information about the Company to the public in Hong Kong and not for any other purposes. No investment decision should be based on the information contained in this document; (b) the publication of this document or supplemental, revised or replacement pages on the Stock Exchange’s website does not give rise to any obligation of the Company, its sole sponsor, advisors or members of the underwriting syndicate to proceed with an offering in Hong Kong or any other jurisdiction. -
OVESTIN PESSARY (0.5Mg)
NEW ZEALAND DATA SHEET 1. OVESTIN PESSARY (0.5mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 0.5 mg Estriol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pessary 0.5 mg - white, torpedo formed pessary. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Atrophy of the lower urogenital tract related to oestrogen deficiency, notably • for the treatment of vaginal complaints such as dyspareunia, dryness and itching. • for the prevention of recurrent infections of the vagina and lower urinary tract. • in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery. A diagnostic aid in case of a doubtful atrophic cervical smear. 4.2 Dose and method of administration Dosage OVESTIN is an oestrogen-only product that may be given to women with or without a uterus. Atrophy of the lower urogenital tract 1 pessary per day for the first weeks, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 pessary twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery 1 pessary per day in the 2 weeks before surgery; 1 pessary twice a week in the 2 weeks after surgery. A diagnostic aid in case of a doubtful atrophic cervical smear 1 pessary on alternate days in the week before taking the next smear. Administration OVESTIN pessaries should be inserted intravaginally before retiring at night. -
CPSC 2011 Annual Report to the President and Congress
2011 2011 ANNUAL REPORT TO THE PRESIDENT AND CONGRESS United States Consumer Product Safety Commission United States Consumer Product Safety Commission Chairman Inez Tenenbaum Vice Chairman Commissioner Robert Adler Nancy Nord Commissioner Anne Northup Report to the President and Congress Pursuant to Section 209 of the Consumer Product Safety Improvement Act of 2008 The United States Consumer Product Safety Commission (CPSC) is submitting this report to the President, Congress, and the public, as required under section 27(j) (15 U.S.C. 2076(j)) of the Consumer Product Safety Act (CPSA), as amended by the Consumer Product Safety Improvement Act of 2008 (CPSIA). The content of this report is specified in the CPSA and the CPSIA. The report describes many of the activities performed to protect the public from hazardous consumer products. Readers may also be interested in the CPSC’s 2011 Performance and Accountability Report, required by the Government Performance and Results Act. All reports are available on the CPSC’s website at: www.cpsc.gov. The CPSC (or the Commission), established by Congress in 1972, is the federal regulatory body tasked with protecting children and families from unreasonable risks of injuries associated with consumer products. In 2010, the Commission launched a comprehensive strategic planning initiative to update its existing strategic plan and help align agency priorities to meet the challenges of the twenty-first century. For example, globalization and technological advances have increased the range of products on the market, as well as the challenges involved in overseeing and regulating thousands of product types that can be assembled across multiple countries. -
UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse
UK Clinical Guideline for best practice in the use of vaginal pessaries for pelvic organ prolapse March 2021 Developed by members of the UK Clinical Guideline Group for the use of pessaries in vaginal prolapse representing: the United Kingdom Continence Society (UKCS); the Pelvic Obstetric and Gynaecological Physiotherapy (POGP); the British Society of Urogynaecology (BSUG); the Association for Continence Advice (ACA); the Scottish Pelvic Floor Network (SPFN); The Pelvic Floor Society (TPFS); the Royal College of Obstetricians and Gynaecologists (RCOG); the Royal College of Nursing (RCN); and pessary users. Funded by grants awarded by UKCS and the Chartered Society of Physiotherapy (CSP). This guideline was completed in December 2020, and following stakeholder review, has been given official endorsement and approval by: • British Association of Urological Nurses (BAUN) • International Urogynecological Association (IUGA) • Pelvic Obstetric and Gynaecological Physiotherapy (POGP) • Scottish Pelvic Floor Network (SPFN) • The Association of Continence Advice (ACA) • The British Society of Urogynaecology (BSUG) • The Pelvic Floor Society (TPFS) • The Royal College of Nursing (RCN) • The Royal College of Obstetricians and Gynaecologists (RCOG) • The United Kingdom Continence Society (UKCS) Review This guideline will be due for full review in 2024. All comments received on the POGP and UKCS websites or submitted here: [email protected] will be included in the review process. 2 Table of Contents Table of Contents ................................................................................................................................ -
Pessary for Management of Pelvic Organ Prolapse
Pessary for management of Pelvic Organ Prolapse Cathy Davis Clinical Nurse Specialist Department of Urogynaecology King’s College Hospital, London Definition of Prolapse The descent of one or more of the anterior vaginal wall, posterior vaginal wall, uterus (cervix) or vaginal vault (cuff scar after hysterectomy). The presence of any such sign should be correlated with relevant POP symptoms. (Haylen et al 2016) Risk Factors • Increased intra-abdominal pressure • Chronic cough • Chronic constipation • Weight lifting • Presence of abdominal tumours - fibroids & ovarian cysts • High impact exercise • Age/ Menopause • Obesity Risk Factors contd.... • Smoking • Multiparity • Congenital weakness – rare; due to deficiency in collagen metabolism • Injury to pelvic floor muscles • Iatrogenic/ pelvic surgery - hysterectomy Symptoms of POP • May be asymptomatic – a small amount of prolapse can often be normal • Sensation of a lump or bulge " coming down" - most common • Backache • Heaviness • Dragging or discomfort inside the vagina – often worse on standing /sitting for prolonged periods • Seeing a lump or bulge Symptoms of POP contd.... • Bladder / Urinary symptoms -Frequency -Difficulty initiating voids, low-flow, incomplete bladder emptying -Leakage on certain movements or when lifting heavy objects -Recurrent urinary tract infections • Bowel symptoms -Constipation - Incomplete bowel emptying - May have to digitate to defecate/use aides • Symptoms related to Sex – uncomfortable, lack of sensation Diagnosis of Prolapse • Vaginal examination • -
Combi Soft Gel Pessary & External Cream
Combi Soft Gel Pessary Canesten & External Cream 500mg vaginal capsule & 2% w/w cream Clotrimazole Read all of this leaflet carefully because it contains important To treat internal thrush, your doctor may recommend that you use the information for you. pessary without the help of an applicator. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. HOW TO USE CANESTEN® COMBI • This medicine has been prescribed for you. Do not give it to anyone else 3. under any circumstances. The Soft Gel Pessary: • If you have any unusual effects after using this product, tell your doctor. Unless directed otherwise by your doctor, the Soft Gel Pessary should be inserted as high as possible into the vagina, preferably before going to sleep IN THIS LEAFLET at night for convenient and comfortable treatment. Wash your hands before removing the foil from the blister pack and again 1. What is Canesten Combi and what is it used for? afterwards when you have used the applicator. 2. Before you use Canesten Combi 3. How to use Canesten Combi 1. Remove the applicator from the packaging. Pull out the plunger A until it 4. Possible side effects stops. Remove the pessary from the foil blister pack and place firmly into the 5. How to store Canesten Combi applicator B. 6. Further information 1. WHAT IS CANESTEN® COMBI AND WHAT IS IT USED FOR? Canesten Combi Soft Gel Pessary & External Cream is a full course of treatment for vaginal thrush (candidiasis) because it treats both the internal cause and external symptoms. -
Bowel Preparation Instructions Fleet Enema
66 BOWEL PREPARATION INSTRUCTIONS FLEET ENEMA Please read these instructions before you have your enema and follow carefully. If you need more advice before using the enema, please telephone the Endoscopy Unit on Tel: 01246 512197 You have been given a phosphate enema, which should be kept and used at room temperature. This is to be used on the day you are coming to hospital for your flexible sigmoidoscopy procedure. Instructions: • The enema must be given at least one hour before you leave home to attend hospital. e.g. if your appointment is at 2.00pm and you will be leaving at 1.30pm you must give the enema at 12.30pm. • To give the enema, you need to lie down on your side with both knees bent and pulled up towards your chest. • Remove the enema cap and throw it away. • Relax and gently insert the full length of the nozzle into your rectum (back passage). • Do this without using undue force. The tip of the nozzle is already lubricated to make insertion easier • Squeeze the bottle until it is completely empty. The bottle may be rolled up (like a tube of toothpaste) ensure it empties. Then gently withdraw the bottle while still squeezing to keep it rolled up. • Hold the liquid in your back passage for as long as you can (by clenching your buttocks) 66 MAKE SURE YOU ARE CLOSE TO A TOILET AS THE ENEMA WILL RESULT IN A RAPID EMPTYING OF YOUR BOWELS • Return the used enema to its carton and throw away safely in your domestic waste. -
About Your Surgery Pre-Operative Instructions Prior to Surgery Post-Operative Instructions How to Reach Us
www.fpminstitute.com About Your Surgery Pre-operative Instructions Prior to Surgery Post-operative Instructions How to Reach Us www.fpminstitute.com Pre-operative Instructions Please Note Patient Name: Procedure: Vaginal Colpopexy Enterocele / Rectocele Repair A physician at The Institute for Female Pelvic Medicine & Sacral Colpopexy Colpocleisis / Colpectomy Reconstructive Surgery is available for emergencies 24 hours per day. Hysterectomy Removal / Revision Uterosacral Vault Suspension InterStim® Office hours are Monday through Friday, 8 a.m. to 4 p.m. Colporrhaphy Pubovaginal Sling After hours and on weekends, you can leave non-urgent messages Other: that will be returned the next business day. For urgent situations, Surgery Date: the answering service can page the physician on call. Medical Clearance Blood work at Lab Blood work on Admit. You are required to be medically cleared for surgery by your primary care physician and/or cardiologist within 30 days of your scheduled surgery. You have been given a medical clearance form that your physician will need to complete, as well as a script for an EKG and bloodwork. Please contact your physician and schedule your medical clearance appointment for the week of (not before this www.fpminstitute.com date). If your physician sends you to a lab for bloodwork, we suggest you do this at least two to three days before your appointment, but not before the date indicated above. We will need copies of your test results and completed medical clearance form faxed to us at the number on the form at least three (3) business days prior to your surgery. If you have any questions, please contact our nursing department. -
Safe Sleep for Your Baby
SAFE SLEEP FOR YOUR BABY Reduce the Risk of Sudden Infant Death Syndrome (SIDS) and Other Sleep-Related Causes of Infant Death This is what a safe sleep environment looks like. The infant’s sleep area has no bumpers, pillows, blankets, or toys and is in the same room where the parents sleep. 1 Each year in the United States, thousands of babies die suddenly and unexpectedly. Some of these deaths result from unknown causes, such as Sudden Infant Death Syndrome (SIDS), while others are from known causes, including other sleep-related causes of infant death. What is SIDS? SIDS is the sudden, unexpected death—that doesn’t have a known cause even after a full investigation—of a baby between 1 month and 1 year of age. About half of the sudden, unexpected infant deaths that occur in the United States each year are from SIDS. What are other sleep-related causes of infant death? Other sleep-related causes of infant death are those related to how or where a baby slept. These can include accidental: l Suffocation: when something, such as a pillow, or someone covers the baby’s face and nose, blocking the ability to breathe l Entrapment: when the baby gets trapped between two objects, such as a mattress and a wall, and can’t breathe l Strangulation: when something presses on or wraps around the baby’s neck, blocking baby’s airway Fast facts about SIDS l SIDS is the leading cause of death among babies 1 month to 1 year of age. l Most SIDS deaths happen when babies are between 1 month and 4 months of age. -
Snakes, Worms and Catheters: Continuum and Serpentine Robots for Minimally Invasive Surgery
IEEE ICRA 2010 Full Day Workshop Snakes, Worms and Catheters: Continuum and Serpentine Robots for Minimally Invasive Surgery Monday May 3, 2010 Anchorage, Alaska USA Organizers: Pierre E. Dupont Mohsen Mahvash Workshop Contents 1- Introduction 2- Abstract of Invited Talks • Neal Tanner, Hansen Medical (commercialization) 3 • David Camarillo, Hansen Medical (robotic catheters) 5 • Howie Choset, Carnegie Mellon University (snakes) 6 • Pierre Dupont, Children’s Hospital Boston, HMS (continuum robots) 8 • Koji Ikuta, Nagoya University (robotic catheters) 9 • Joseph Madsen, MD, Children’s Hospital, Harvard Med (clinical perspective) 11 • Mohsen Mahvash, Children’s Hospital Boston, HMS (continuum robots) 12 • Rajni Patel, University of Western Ontario (robotic catheters) 14 • Cameron Riviere, Carnegie Mellon University (worm robots) 16 • Nabil Simaan, Columbia University (NOTES) 17 • Russell Taylor, Johns Hopkins University (snake robots) 19 • Robert Webster, Vanderbilt University (continuum robots) 20 • Guang-Zhong Yang, Imperial College (snake robots) 23 3- Short Papers • A Highly Articulated Robotic System (CardioARM) is Safer than a Rigid System for Intrapericardial Intervention in a Porcine Model 24 • Towards a Minimally Invasive Neurosurgical Intracranial Robot 27 • Uncertainty Analysis in Continuum Robot Kinematics 30 • Ultrasound Image-Controlled Robotic Cardiac Catheter System 33 • Steerable Continuum Robot Design for Cochlear Implant Surgery 36 • Modular Needle Steering Driver for MRI-guided Transperineal Prostate Intervention 39 -
Infant Safe Sleep Baby Education Program
INFANT SAFE SLEEP BABY EDUCATION PROGRAM In collaboration with 1 Objectives • Background on Safe Sleep Baby Campaign in Sacramento • Define infant sleep-related deaths terms • Knowledge of UC Davis Children’s Hospital P & P 4124 • Understand the AAP’s 2016 recommendations for infant safe sleep, including Risk Factors • Understand the 6 Steps to Safe Sleep Baby 2 Fast Facts • Every other week in Sacramento County, a baby dies while sleeping • A Significant Number of these babies are African American • Nearly all of them were found in unsafe sleep environments • Infant Sleep-Related Deaths are PREVENTABLE 3 Cause of Death: Co-sleeping, Infant Bed Alexa La’Ray Died at 4 days old Died at 6 weeks old 4 Risk Factors1 • Sleeping in a non-infant bed • Sleeping with others (adults and other children) • Sleeping with objects around baby, such as pillows, blankets, bumpers, stuffed animals, etc. • Sleeping in prone or side position 1 Task Force on Sudden Infant Death Syndrome, SIDS and other sleep-related infant deaths: expansion of recommendations for a safe infant sleeping environment. Pediatrics 2011;128e 1341-67 5 CHILDChild DEATH Death REVIEW Review TEAM Team DATA Data INFANT SLEEP-RELATED DEATHS Infant Sleep-Related Deaths • Every other week in Sacramento County a baby died while sleeping Cause of Death, 2013-2014 # of Deaths Infant Sleep-Related Deaths (incl. SIDS, SUIDS & 11 Undetermined) Drowning 4 CAN Homicide 3 Motor Vehicle Crashes 3 • Nearly all babies are found in unsafe sleep conditions • Leading cause of death for babies one month to one year of age – (~90% within first six months) • Occur in all socio-economic, racial and ethnic groups • A significant number of them are African American.